The development of small-molecule inhibitors targeting CD47
- 1 February 2021
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 26 (2) , 561-568
Abstract
No abstract availableKeywords
Funding Information
- The Science and Technology Development Fund
This publication has 85 references indexed in Scilit:
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumorsProceedings of the National Academy of Sciences, 2012
- CD47–signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destructionProceedings of the National Academy of Sciences, 2011
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin LymphomaCell, 2010
- Self inhibition of phagocytosis: The affinity of ‘marker of self’ CD47 for SIRPα dictates potency of inhibition but only at low expression levelsBlood Cells, Molecules, and Diseases, 2010
- Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cellsProceedings of the National Academy of Sciences, 2009
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid PhagocytosisCell, 2009
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem CellsCell, 2009
- Inhibition of “self” engulfment through deactivation of myosin-II at the phagocytic synapse between human cellsJournal of Cell Biology, 2008